References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2024-4-121-127

mrj-1630

Research Article

ОБЗОРЫ

REVIEWS

Об иммунотропных эффектах нового комбинированного фармаконутрицевтика при остеоартрите

On the immunotropic effects of a new combined pharmaconutraceutical preparation in osteoarthritis

https://orcid.org/0000-0002-5933-5732

Сарвилина

И. В.

Sarvilina

I. V.

344002, Ростов-на-Дону, ул. Социалистическая, 74

74, Socialisticheskaya Street, Rostov-on-Don 344002

isarvilina@mail.ru

https://orcid.org/0000-0002-6068-3080

Лила

А. М.

Lila

A. M.

кафедра ревматологии

115522, Москва, Каширское шоссе, 34А;125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of Rheumatology

34A, Kashirskoe Shosse, Moscow 115522;2/1, Barrikadnaya Street, Build. 1, Moscow 125993

https://orcid.org/0000-0002-7663-710X

Громова

О. А.

Gromova

O. A.

119333, Москва, ул. Вавилова, 44

44, Vavilov Street, Moscow 119333

ООО «Медицинский центр «Новомедицина»РоссияLLC "Medical Center" Novomeditsina"Russian Federation

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationRussian Federation

Федеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center "Informatics and Management"Russian Federation

2024

21082024

184121127

2024

Сарвилина И.В., Лила А.М., Громова О.А.

Sarvilina I.V., Lila A.M., Gromova O.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1630

Остеоартрит (ОА) является одной из основных причин инвалидности в мире, однако эффективность и безопасность его терапии остаются крайне низкими. В обзоре представлены эпидемиология ОА, а также механизм развития и современные возможности фармакологической регуляции иммуноопосредованного воспаления при ОА. Проанализированы иммунные звенья феномена оральной толерантности и перспективы его использования для подавления аутовоспаления при ОА на основе применения комбинированного фармаконутрицевтика Хондрогард® ТРИО как элемента нутритивной поддержки пациентов с этим заболеванием. Подчеркивается целесообразность формирования научно обоснованного рационального подхода к лечению ОА, облегчающего симптомы, уменьшающего аутовоспалительное повреждение суставного хряща и улучшающего его регенерацию с участием компонентов внеклеточного матрикса.

Osteoarthritis (OA) is one of the leading causes of disability in the world, but the efficacy and safety of its treatment remain extremely low. This review presents epidemiology of OA, mechanism of its development and modern possibilities of pharmacological regulation of immune-mediated inflammation in OA. We analyze the immunological aspects of oral tolerance phenomenon and the prospects for its use to suppress autoinflammation in OA using combined pharmaconutraceutical preparation Chondroguard® TRIO as an element of nutritional support for patients with this disease. It is emphasized that it is advisable to develop a scientifically based rational approach to the treatment of OA that alleviates symptoms, reduces autoinflammatory affection of articular cartilage and improves its regeneration with the involvement of extracellular matrix components.

остеоартриторальная толерантностьнеденатурированный коллаген II типахондроитина сульфатглюкозамина сульфат

osteoarthritisoral toleranceundenatured collagen type IIchondroitin sulfateglucosamine sulfate

Статья опубликована при поддержке компании ЗАО «ФармФирма «Сотекс».

Publication of this article has been supported by Sotex PharmFirma.

References1

Peat G, Thomas M. Osteoarthritis Year in Review 2020: Epidemiology & Therapy. Osteoarthritis Cartilage. 2021 Feb;29(2):180-189. doi: 10.1016/j.joca.2020.10.007. Epub 2020 Nov 23.

Hunter D, March L, Chew M. Osteoarthritis in 2020 and beyond: A Lancet commission. Lancet. 2020 Nov 28;396(10264):1711-1712. doi: 10.1016/S0140-6736(20)32230-3. Epub 2020 Nov 4.

Deshpande B, Katz JN, Solomon DH, et al. Number of persons with symptomatic knee osteoarthritis in the us: Impact of race and ethnicity, age, sex, and obesity. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1743-1750. doi: 10.1002/acr.22897. Epub 2016 Nov 3.

Driban J, Harkey M, Liu SH, et al. Osteoarthritis and aging: Young adults with osteoarthritis. Curr Epidemiol Rep. 2020;7(1): 9–15. doi:10.1007/s40471-020-00224-7.

Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013 Sep;21(9):1145-53. doi: 10.1016/j.joca.2013.03.018.

Maldonado M, Nam J. The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis. Biomed Res Int. 2013:2013: 284873. doi: 10.1155/2013/284873. Epub 2013 Aug 28.

Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J. 2003 Jul;79(933):377-83. doi: 10.1136/pmj.79.933.377.

Loeser R, Collins J, Diekman B. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Jul;12(7):412-20. doi: 10.1038/nrrheum.2016.65. Epub 2016 May 19.

Greene M, Loeser R. Aging-related infammation in osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1966-71. doi: 10.1016/j.joca.2015.01.008.

Santiago A, Alves AC, Oliveira RP, et al. Aging correlates with reduction in regulatorytype cytokines and T cells in the gut mucosa. Immunobiology. 2011 Oct;216(10):1085-93. doi: 10.1016/j.imbio.2011.05.007. Epub 2011 May 14.

Permuy M, Guede D, Lуpez-Peсa M, et al. Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits. BMC Musculoskelet Disord. 2015 May 20:16:120. doi: 10.1186/s12891-015-0572-8.

Stewart M, Cibere J, Sayre E, Kopec J. Efficacy of commonly prescribed analgesics in the management of osteoarthritis: a systematic review and meta-analysis. Rheumatol Int. 2018 Nov;38(11):1985-1997. doi: 10.1007/s00296-018-4132-z. Epub 2018 Aug 17.

Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337-350. doi: 10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.

Reginster J, Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. 2021 Jan;33(1):37-47. doi: 10.1007/s40520-020-01643-8. Epub 2020 Jul 7.

Hochberg M, Martel-Pelletier J, Monfort J, et al. MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan; 75(1):37-44. doi: 10.1136/annrheumdis-2014-206792. Epub 2015 Jan 14.

Минасов ТБ, Лила АМ, Назаренко АГ и др. Морфологические проявления действия высокоочищенного хондроитина сульфата у пациентов с декомпенсированной формой остеоартрита коленных суставов. Современная ревматология. 2022; 16(6):55-63.

Minasov TB, Lila AM, Nazarenko AG, et al. Morphological reflection of highly purified chondroitin sulfate action in patients with decompensated form of knee osteoarthritis. Sovremennaya revmatologiya = Modern Rheumatology Jpurnal. 2022;16(6):55-63. (In Russ.). doi: 10.14412/1996-7012-2022-6-55-63

Honvo G, Lengele L, Charles A, et al. Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatol Ther. 2020 Dec;7(4):703-740. doi: 10.1007/s40744-020-00240-5. Epub 2020 Oct 17.

Li Y, Luo W, Zhu S, Lei G. T Cells in Osteoarthritis: Alterations and Beyond. Front Immunol. 2017 Mar 30:8:356. doi: 10.3389/fimmu.2017.00356. eCollection 2017.

Hussein M, Fathi N, El-Din A, et al. Alterations of the CD4(+), CD8 (+) T cell subsets, interleukins1beta, IL-10, IL-17, tumor necrosis factor-alpha and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res. 2008 Sep;14(3):321-8. doi: 10.1007/s12253-008-9016-1. Epub 2008 Apr 8.

Zhang J, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007 Spring; 45(2):27-37. doi: 10.1097/AIA.0b013e318034194e.

Wan Y, Flavell R. 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev. 2007 Dec:220:199-213. doi: 10.1111/j.1600-065X.2007.00565.x.

Ricciotti E, FitzGerald G. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000. doi: 10.1161/ATVBAHA.110.207449.

Martel-Pelletier J, Mineau F, Fahmi H, et al. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthritis Rheum. 2004 Dec;50(12):3925-33. doi: 10.1002/art.20632.

He W, Pelletier J, Martel-Pelletier J, et al. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol. 2002 Mar;29(3):546-53.

Rigoglou S, Papavassiliou A. The NF-κB signalling pathway in osteoarthritis. Int. Int J Biochem Cell Biol. 2013 Nov;45(11):2580-4. doi: 10.1016/j.biocel.2013.08.018. Epub 2013 Sep 1.

Korotkyi O, Vovk A, Halenova T, et al. Cytokines profle in knee cartilage of rats during monoiodoacetate-induced osteoarthritis and administration of probiotic. Biopolym Cell. 2020;36(1):22–34. doi:10.7124/bc.000A1E.

Houard X, Goldring M, Berenbaum F. Homeostatic mechanisms in articular cartilage and role of infammation in osteoarthritis. Curr Rheumatol Rep. 2013 Nov;15(11):375. doi: 10.1007/s11926-013-0375-6.

Korotkyi O, Luhovska T, Serhiychuk T. The gut microbiota of rats under experimental osteoarthritis and administration of chondroitin sulfate and probiotic. Mikrobiol Z. 2020;82(6), 64–73. doi:10.15407/microbiolj82.06.064.

Wu YL, Xu J, Rong XY, et al. Gut microbiota alterations and health status in aging adults: From correlation to causation. Aging Med (Milton). 2021 Jun 24;4(3):206-213. doi: 10.1002/agm2.12167. eCollection 2021 Sep.

Hsia A, Jbeily EH, Mendez ME, et al. Post-traumatic osteoarthritis progression is diminished by early mechanical unloading and anti-infammatory treatment in mice. Osteoarthritis Cartilage. 2021 Dec;29(12):1709-1719. doi: 10.1016/j.joca.2021.09.014. Epub 2021 Oct 13.

Heijink A, Gomoll AH, Madry H, et al. Biomechanical considerations in the pathogenesis of osteoarthritis of the knee. Knee Surg Sports Traumatol Arthrosc. 2012 Mar;20(3): 423-35. doi: 10.1007/s00167-011-1818-0. Epub 2011 Dec 16.

Chen JJ, Huang JF, Du WX, Tong PJ. Expression and signifcance of MMP3 in synovium of knee joint at diferent stage in osteoarthritis patients. Asian Pac J Trop Med. 2014 Apr;7(4):297-300. doi: 10.1016/S1995-7645(14)60042-0.

Sun C, Cao C, Zhao T, et al. A2M inhibits infammatory mediators of chondrocytes by blocking IL-1 /NF- B pathway. J Orthop Res. 2023 Jan;41(1):241-248. doi: 10.1002/jor.25348. Epub 2022 May 4.

Wan Y, Flavell R. “Yin-Yang” functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev. 2007 Dec:220:199-213. doi: 10.1111/j.1600-065X.2007.00565.x.

Gencoglu H, Orhan C, Sahin E, Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: A review on the current knowledge of companion animals. Animals (Basel). 2020 Apr 17;10(4):697. doi: 10.3390/ani10040697.

Faria A, Weiner H. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006 Jun-Dec;13(2-4): 143-57. doi: 10.1080/17402520600876804.

Slavin A, Maron R, Weiner H. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol. 2001 Jun;13(6):825-33. doi: 10.1093/intimm/13.6.825.

Inobe J, Slavin A, Komagata Y, et al. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol. 1998 Sep;28(9): 2780-90. doi: 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J.

Kuhn C, Weiner H. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016 Jul;8(8):889-906. doi: 10.2217/imt-2016-0049. Epub 2016 May 10.

Bertolini T, Biswas M, Terhorst C, et al. Role of orally induced regulatory T cells in immunotherapy and tolerance. Cell Immunol. 2021 Jan:359:104251. doi: 10.1016/j.cellimm.2020.104251. Epub 2020 Nov 14.

Hooper L, Littman D, Macpherson A. Interactions between the microbiota and the immune system. Science. 2012 Jun 8;336(6086): 1268-73. doi: 10.1126/science.1223490. Epub 2012 Jun 6.

Esterhazy D, Canesso M, Mesin L, et al. Compartmentalized gut lymph node drainage dictates adaptive immune responses. Nature. 2019 May;569(7754):126-130. doi: 10.1038/s41586-019-1125-3. Epub 2019 Apr 15.

Pabst O, Mowat A. Oral tolerance to food protein. Mucosal Immunol. 2012 May;5(3): 232-9. doi: 10.1038/mi.2012.4. Epub 2012 Feb 8.

Goubier A, Dubois B, Gheit H, et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity. 2008 Sep 19;29(3):464-75. doi: 10.1016/j.immuni.2008.06.017.

Zheng M, Tian Z. Liver-mediated adaptive immune tolerance. Front Immunol. 2019 Nov 5:10:2525. doi: 10.3389/fimmu.2019.02525. eCollection 2019.

Tordesillas L, Berin M. Mechanisms of Oral Tolerance. Clin Rev Allergy Immunol. 2018 Oct;55(2):107-117. doi: 10.1007/s12016-018-8680-5.

Cassani B, Villablanca E, Quintana F, et al. Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology. 2011 Dec;141(6):2109-18. doi: 10.1053/j.gastro.2011.09.015. Epub 2011 Sep 16.

Rezende R, Oliveira R, Medeiros S, et al. Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells. J Autoimmun. 2013 Feb:40:45-57. doi: 10.1016/j.jaut.2012.07.012. Epub 2012 Aug 28.

Cao D, Borjesson O, Larsson P, et al. FOXP3 identifies regulatory CD25bright CD4+ T cells in rheumatic joints. Scand J Immunol. 2006 Jun;63(6):444-52. doi: 10.1111/j.1365-3083.2006.001755.x.

Mora J, von Andrian U. Differentiation and homing of IgA-secreting cells. Mucosal Immunol. 2008 Mar;1(2):96-109. doi: 10.1038/mi.2007.14. Epub 2008 Jan 23.

Faria A, Gomes-Santos A, Goncalves J, et al. Food components and the immune system: from tonic agents to allergens. Front Immunol. 2013 May 17:4:102. doi: 10.3389/fimmu.2013.00102. eCollection 2013.

Oida T, Weiner H. TGF-β induces surface LAP expression on murine CD4 T cells independent of Foxp3 induction. PLoS One. 2010 Nov 24;5(11):e15523. doi: 10.1371/journal.pone.0015523.

Ochi H, Abraham M, Ishikawa H, et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25-LAP+T cells. Nat Med. 2006 Jun;12(6):627-35. doi: 10.1038/nm1408. Epub 2006 May 21.

Gagliani N, Magnani C, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013 Jun;19(6):739-46. doi: 10.1038/nm.3179. Epub 2013 Apr 28.

Mazzini E, Massimiliano L, Penna G, et al. Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1+ macrophages to CD103+ dendritic cells. Immunity. 2014 Feb 20;40(2):248-61. doi: 10.1016/j.immuni.2013.12.012. Epub 2014 Jan 23.

Hadis U, Wahl B, Schulz O, et al. Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity. 2011 Feb 25;34(2): 237-46. doi: 10.1016/j.immuni.2011.01.016. Epub 2011 Feb 17.

Worbs T, Bode U, Yan S, et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med. 2006 Mar 20;203(3):519-27. doi: 10.1084/jem.20052016. Epub 2006 Mar 13.

Margenthaler J, Landeros K, Kataoka M, et al. CD1-dependent natural killer (NK1.1+) T cells are required for oral and portal venous tolerance induction. J Surg Res. 2002 May 1; 104(1):29-35. doi: 10.1006/jsre.2002.6400.

Rezende R, Da Cunha A, Kuhn C, et al. Identification and characterization of latencyassociated peptide-expressing γδT cells. Nat Commun. 2015 Dec 8:6:8726. doi: 10.1038/ncomms9726.

Ke Y, Kapp J. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol. 1996 Feb 1; 156(3):916-21.

Chen M, Yan B, Kozoriz D, et al. Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. Eur J Immunol. 2009 Dec;39(12):3423-35. doi: 10.1002/eji.200939441.

Mortha A, Chudnovskiy A, Hashimoto D, et al. Microbiota dependent crosstalk between macrophages and ILC promotes intestinal homeostasis. Science. 2014 Mar 28;343(6178): 1249288. doi: 10.1126/science.1249288. Epub 2014 Mar 13.

Данилов АлБ, Лила АМ, Маджидова ЁН и др. Новый фармаконутрицевтик Хондрогард®ТРИО для профилактики заболеваний опорно-двигательного аппарата и нутритивной поддержки пациентов с остеоартритом и неспецифической болью в спине: оценка клинических возможностей. Резолюция мультидисциплинарного экспертного совета. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):134-146. doi: 10.14412/2074-2711-2023-2-134-146

Danilov AlB, Lila AM, Majidova YoN, et al. New pharmaconutraceutical Chondroguard® TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):134-146. (In Russ.). doi: 10.14412/2074-2711-2023-2-134-146

Hay ED. Nature and cellular origin of connective tissue matrix. Ups J Med Sci. 1977; 82(2):99-100. doi: 10.3109/03009737709179081.

Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.

Park K, Park M, Cho M, et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol. 2009;19(6):581-9. doi: 10.1007/s10165-009-0210-0. Epub 2009 Aug 21.

Lugo J, Saiyed Z, Lau F, et al. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebocontrolled study in healthy volunteers. J Int Soc Sports Nutr. 2013 Oct 24;10(1):48. doi: 10.1186/1550-2783-10-48.

Schadow S, Simons V, Lochnit G, et al. Metabolic Response of Human Osteoarthritic Cartilage to Biochemically Characterized Collagen Hydrolysates. Int J Mol Sci. 2017 Jan 20;18(1):207. doi: 10.3390/ijms18010207.

Bakilan F, Armagan O, Ozgen M, et al. Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial. Eurasian J Med. 2016 Jun;48(2): 95-101. doi:10.5152/eurasianjmed.2015.15030.

Cabezas M, Benito J, Ortega Б, GarciaPedraza E. Long-term supplementation with an undenatured type-II collagen (UC-II®) formulation in dogs with degenerative joint disease: Exploratory study. Open Vet J. 2022 Jan-Feb;12(1):91-98. doi: 10.5455/OVJ.2022.v12.i1.11. Epub 2022 Feb 5.

Crowley D, Lau F, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6): 312-21. doi: 10.7150/ijms.6.312.

Gupta R, Canerdy TD, Skaggs P, et al. Terapeutic efcacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses1. J Vet Pharmacol Ther. 2009 Dec;32(6):577-84. doi: 10.1111/j.1365-2885.2009.01079.x.

Kale S, Yende S. Effects of Aging on Inflammation and Hemostasis through the Continuum of Critical Illness. Aging Dis. 2011 Dec; 2(6):501-11. Epub 2011 Dec 2.

Kato H, Fujihashi K, Kato R, et al. Lack of oral tolerance in aging is due to sequential loss of Peyer’s patch cell interactions. Int Immunol. 2003 Feb;15(2):145-58. doi: 10.1093/intimm/dxg011.

Wilson B, Novakofski K, Donocof R, et al. Telomerase activity in articular chondrocytes is lost afer puberty. Cartilage. 2014 Oct;5(4): 215-20. doi: 10.1177/1947603514537518.

Jomphe C, Gabriac M, Hale T, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1): 59-65. doi: 10.1111/j.1742-7843.2007.00158.x. Epub 2007 Nov 5.

Da Cunha A, Aguiar J, Correa da Silva F, Michelacci Y. Do chondroitin sulfates with different structures have different activities on chondrocytes and macrophages? Int J Biol Macromol. 2017 Oct:103:1019-1031. doi: 10.1016/j.ijbiomac.2017.05.123. Epub 2017 May 20.

Taraballi F, Corradetti B, Minardi S, et al. Biomimetic collagenous scaffold to tune inflammation by targeting macrophages. J Tissue Eng. 2016 Feb 1:7:2041731415624667. doi: 10.1177/2041731415624667. eCollection 2016 Jan-Dec.

Ohtake Y, Wong D, Abdul-Muneer P, et al. Two PTP receptors mediate CSPG inhibition by convergent and divergent signaling pathways in neurons. Sci Rep. 2016 Nov 16:6:37152. doi: 10.1038/srep37152.

Ma L, Rudert W, Harnaha J, et al. Immunosuppressive effects of glucosamine. J Biol Chem. 2002 Oct 18;277(42):39343-9. doi: 10.1074/jbc.M204924200. Epub 2002 Aug 9.

Chiusaroli R, Piepoli T, Zanelli T, et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011:2011:939265. doi: 10.1155/2011/939265. Epub 2011 Oct 9.

Marti-Bonmati L, Sanz-Requena R, Rodrigo J, et al. Glucosamine sulfate effect on the degenerated patellar cartilage: preliminary findings by pharmacokinetic magnetic resonance modeling. Eur Radiol. 2009 Jun;19(6): 1512-8. doi: 10.1007/s00330-008-1286-1. Epub 2009 Feb 13.

Di Cesare Mannelli L, Micheli L, Zanardelli M, Ghelardini C. Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskelet Disord. 2013 Aug 1:14:228. doi: 10.1186/1471-2474-14-228.

The authors declare that there are no conflicts of interest present.